EUVIMEDEUVIMED entdecken
Crossref

Acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy through USP46 activation

Qing Hou iD, Guiqin Huang iD, Shuyan Kan, Ruixiang Yang iD, Zijian Ma iD, Xiaodong Zhu iD, Caihong Zeng iD, Song Jiang iD, Zhihong Liu iD

Science Translational Medicine · 11.03.2026 · 18 (840)

DOI: 10.1126/scitranslmed.ads4585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 11.03.2026. Verfasst von Qing Hou und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210018, Jiangsu, China. Hauptthemen laut MEDLINE: Podocytes, Diabetic Nephropathies, Acarbose, Kidney Glomerulus. Die Arbeit nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National key R&D program of China, National Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ubiquitin-proteasome system (UPS) is important for podocyte health, but the specific UPS proteins involved in podocyte injury of diabetic nephropathy (DN) are not well known. Patients with DN have lower expression of USP46 in podocytes, which is linked to higher proteinuria. Deleting the Usp46 gene in podocytes of mice (Usp46 PKO mice) led to spontaneous albuminuria and worsened podocyte injury and glomerular lesions under diabetic conditions. Mechanically, loss of USP46 caused cytosolic translocation and aggregation of TAR DNA binding protein 43 (TDP-43) in podocytes. Here, we identified acarbose as an agonist of USP46. Treatment with acarbose reduced TDP-43 aggregation in podocytes, prevented podocyte loss, and mitigated albuminuria in diabetic mice; the therapeutic efficacy of acarbose was abolished in Usp46 PKO mice. This research elucidates the role of USP46 in podocyte homeostasis and injury in DN and indicates a potential therapeutic impact for acarbose in DN beyond the regulation of blood glucose concentrations through its activation of USP46.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PodocytesDiabetic NephropathiesAcarboseKidney GlomerulusEndopeptidasesAnimalsHumansMice, KnockoutDNA-Binding ProteinsMiceDiabetes Mellitus, ExperimentalAlbuminuriaEnzyme Activation

Substanzen

AcarboseDNA-Binding ProteinsEndopeptidases

Autor:innen und Institutionen

  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210018, Jiangsu, China.

ORCID-Profile: Qing Hou, Guiqin Huang, Ruixiang Yang, Zijian Ma, Xiaodong Zhu, Caihong Zeng, Song Jiang, Zhihong Liu

Förderung

  • National Natural Science Foundation of China
  • National key R&D program of China
  • National Natural Science Foundation
  • The Open Project of Jiangsu Biobank of Clinical Resources

Zitieren

APA

Hou, Q., Huang, G., Kan, S., Yang, R., Ma, Z., Zhu, X., Zeng, C., Jiang, S., & Liu, Z. (2026). Acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy through USP46 activation. Science Translational Medicine, 18(840). https://doi.org/10.1126/scitranslmed.ads4585

Vancouver

Hou Q, Huang G, Kan S, Yang R, Ma Z, Zhu X, et al. Acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy through USP46 activation. Science Translational Medicine. 2026;18(840). doi:10.1126/scitranslmed.ads4585

BibTeX
@article{Hou2026,
  author = {Hou, Qing and Huang, Guiqin and Kan, Shuyan and Yang, Ruixiang and Ma, Zijian and Zhu, Xiaodong and Zeng, Caihong and Jiang, Song and Liu, Zhihong},
  title = {Acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy through USP46 activation},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {840},
  doi = {10.1126/scitranslmed.ads4585}
}
Kostenlos starten →